Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back

被引:3
作者
Rossi, Valentina [1 ]
Turati, Alessandra [1 ]
Rosato, Antonio [1 ,2 ]
Carpanese, Debora [1 ]
机构
[1] Veneto Inst Oncol IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy
[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
关键词
triple negative breast cancer (TNBC); sacituzumab govitecan (IMMU-132); antibody-drug conjugate (ADC); Trop-2; immunotherapy; target therapeutics; metastatic TNBC; ANTIBODY-DRUG CONJUGATE; PROSTATE-CANCER; TROP2; RESISTANCE; MECHANISMS; BIOMARKER; EFFICACY; ANTIGEN;
D O I
10.3389/fimmu.2024.1447280
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Triple-negative breast cancer (TNBC) represents a major therapeutic challenge due to its heterogeneous and aggressive phenotype, and limited target-specific treatment options. The trophoblast cell surface antigen (Trop-2), a transmembrane glycoprotein overexpressed in various cancers, has emerged as a promising target for TNBC. Sacituzumab govitecan (SG), an antibody-drug conjugate (ADC) that targets Trop-2, has recently entered treatment algorithms for advanced and metastatic TNBC, independently from Trop-2 expression status, with manageable toxicity. Despite the impressive results, questions remain unsolved regarding its efficacy, safety profile, and Trop-2 biological role in cancer. Currently, Trop-2 cannot be designated as a predictive biomarker in SG treatment, albeit its expression correlates with disease outcome, yet its levels are not uniform across all TNBCs. Additionally, data regarding Trop-2 expression variations in primary and metastatic sites, and its interplay with other biomarkers are still ambiguous but mandatory in light of future applications of SG in other indications and settings. This poses the questions of a careful evaluation of the efficacy and toxicity profile of SG in such early stages of disease, and in personalized and combinatorial strategies. Research and clinical data are mandatory to address SG drawbacks and minimize its benefits, to realize its full potential as therapeutic agent in different epithelial tumors.
引用
收藏
页数:10
相关论文
共 90 条
[1]   Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence [J].
Almansour, Nahlah Makki .
FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
[2]   Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates [J].
Aoyama, Michihiko ;
Tada, Minoru ;
Yokoo, Hidetomo ;
Demizu, Yosuke ;
Ishii-Watabe, Akiko .
PHARMACEUTICAL RESEARCH, 2022, 39 (01) :89-103
[3]   Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [J].
Bardia, A. ;
Tolaney, S. M. ;
Punie, K. ;
Loirat, D. ;
Oliveira, M. ;
Kalinsky, K. ;
Zelnak, A. ;
Aftimos, P. ;
Dalenc, F. ;
Sardesai, S. ;
Hamilton, E. ;
Sharma, P. ;
Recalde, S. ;
Gil, E. C. ;
Traina, T. ;
O'Shaughnessy, J. ;
Cortes, J. ;
Tsai, M. ;
Vahdat, L. ;
Dieras, V ;
Carey, L. A. ;
Rugo, H. S. ;
Goldenberg, D. M. ;
Hong, Q. ;
Olivo, M. ;
Itri, L. M. ;
Hurvitz, S. A. .
ANNALS OF ONCOLOGY, 2021, 32 (09) :1148-1156
[4]   Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [J].
Bardia, A. ;
Messersmith, W. A. ;
Kio, E. A. ;
Berlin, J. D. ;
Vahdat, L. ;
Masters, G. A. ;
Moroose, R. ;
Santin, A. D. ;
Kalinsky, K. ;
Picozzi, V ;
O'Shaughnessy, J. ;
Gray, J. E. ;
Komiya, T. ;
Lang, J. M. ;
Chang, J. C. ;
Starodub, A. ;
Goldenberg, D. M. ;
Sharkey, R. M. ;
Maliakal, P. ;
Hong, Q. ;
Wegener, W. A. ;
Goswami, T. ;
Ocean, A. J. .
ANNALS OF ONCOLOGY, 2021, 32 (06) :746-756
[5]   Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].
Bardia, A. ;
Hurvitz, S. A. ;
Tolaney, S. M. ;
Loirat, D. ;
Punie, K. ;
Oliveira, M. ;
Brufsky, A. ;
Sardesai, S. D. ;
Kalinsky, K. ;
Zelnak, A. B. ;
Weaver, R. ;
Traina, T. ;
Dalenc, F. ;
Aftimos, P. ;
Lynce, F. ;
Diab, S. ;
Cortes, J. ;
O'Shaughnessy, J. ;
Dieras, V ;
Ferrario, C. ;
Schmid, P. ;
Carey, L. A. ;
Gianni, L. ;
Piccart, M. J. ;
Loibl, S. ;
Goldenberg, D. M. ;
Hong, Q. ;
Olivo, M. S. ;
Itri, L. M. ;
Rugo, H. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541
[6]   Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J].
Bardia, A. ;
Mayer, I. A. ;
Vahdat, L. T. ;
Tolaney, S. M. ;
Isakoff, S. J. ;
Diamond, J. R. ;
O'Shaughnessy, J. ;
Moroose, R. L. ;
Santin, A. D. ;
Abramson, V. G. ;
Shah, N. C. ;
Rugo, H. S. ;
Goldenberg, D. M. ;
Sweidan, A. M. ;
Iannone, R. ;
Washkowitz, S. ;
Sharkey, R. M. ;
Wegener, W. A. ;
Kalinsky, K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) :741-751
[7]   Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression [J].
Bardia, Aditya ;
Rugo, Hope S. ;
Tolaney, Sara M. ;
Loirat, Delphine ;
Punie, Kevin ;
Oliveira, Mafalda ;
Brufsky, Adam ;
Kalinsky, Kevin ;
Cortes, Javier ;
O'Shaughnessy, Joyce ;
Dieras, Veronique ;
Carey, Lisa A. ;
Gianni, Luca ;
Piccart-Gebhart, Martine ;
Loibl, Sibylle ;
Yoon, Oh Kyu ;
Pan, Yang ;
Hofsess, Scott ;
Phan, See-Chun ;
Hurvitz, Sara A. .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (15) :1738-1744
[8]   Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer [J].
Bardia, Aditya ;
Mayer, Ingrid A. ;
Diamond, Jennifer R. ;
Moroose, Rebecca L. ;
Isakoff, Steven J. ;
Starodub, Alexander N. ;
Shah, Nikita C. ;
O'Shaughnessy, Joyce ;
Kalinsky, Kevin ;
Guarino, Michael ;
Abramson, Vandana ;
Juric, Dejan ;
Tolaney, Sara M. ;
Berlin, Jordan ;
Messersmith, Wells A. ;
Ocean, Allyson J. ;
Wegener, William A. ;
Maliakal, Pius ;
Sharkey, Robert M. ;
Govindan, Serengulam V. ;
Goldenberg, David M. ;
Vahdat, Linda T. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2141-+
[9]   TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer [J].
Bessede, Alban ;
Peyraud, Florent ;
Besse, Benjamin ;
Cousin, Sophie ;
Cabart, Mathilde ;
Chomy, Francois ;
Rey, Christophe ;
Lara, Oren ;
Odin, Ophelie ;
Nafia, Imane ;
Vanhersecke, Lucile ;
Barlesi, Fabrice ;
Guegan, Jean-Philippe ;
Italiano, Antoine .
CLINICAL CANCER RESEARCH, 2024, 30 (04) :779-785
[10]   Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients [J].
Bignotti, Eliana ;
Todeschini, Paola ;
Calza, Stefano ;
Falchetti, Marcella ;
Ravanini, Maria ;
Tassi, Renata A. ;
Ravaggi, Antonella ;
Bandiera, Elisabetta ;
Romani, Chiara ;
Zanotti, Laura ;
Tognon, Germana ;
Odicino, Franco E. ;
Facchetti, Fabio ;
Pecorelli, Sergio ;
Santin, Alessandro D. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (05) :944-953